Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment

EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma

EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies

EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

Now Viewing

EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma

EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

EP: 11.Complying with REMS Training and Documentation Requirements

EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

EP: 13.Unmet Needs in Multiple Myeloma Care

EP: 14.Treatment Sequencing and Combination Therapies for MM

EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

This is a video synopsis/summary of a Practice Pearls involving Ryan Haumschild, PharmD, MS, MBA; Matthew Pianko, MD; and Anthony Perissinotti, PharmD, BCOP.

As key next steps, Pianko emphasizes developing robust inpatient management guidelines for cytokine release syndrome (CRS) and identifying a project leader to drive coordination across key stakeholders like hospital finance teams to optimize operational workflows and preauthorization requirements. Determining best practices for eventual outpatient administration will be important, whether involving prophylactic tocilizumab, patient hotlines for concerning symptoms, or emergency supply of steroids.

Given the broad catchment area, some patients travel hours for infusions, posing access challenges if CRS develops later. Community oncologists should consider partnering with academic centers for bispecific initiation while developing internal expertise. There are also open questions around long-term management like prevention of immunosuppression and infections that warrantadditional education.

Haumschild agrees partnerships facilitate community oncologist access by enabling resource sharing around guidelines and treatment approaches. More data is needed regarding earlier line of therapy usage, durability of responses, and assessing minimal residual disease status.

Perissinotti emphasizes the need to educate emergency departments, intensive care units, overnight staff, and other providers that may interface with these complex patients. Additionally, the reimbursement environment clearly impacts operational decisions, but most clinicians have limited insight into these financial considerations. Education on reimbursement drivers and implications for inpatient vs outpatient administration would enable more informed, patient-centered decisions.

Video synopsis is AI-generated and reviewed by Pharmacy Times® editorial staff.